Visibility in markets where nobody optimised.
We are a pharmaceutical SEO agency working on technical SEO, international SEO and migration continuity for regulated companies. Pharma search terms are low-volume and high-intent: a handful of qualified visits a month can be worth more than a campaign.
Most of the SEO problems we find in pharma are structural, not editorial: sites that changed domain and lost everything, catalogues Google cannot crawl, and twelve country sites competing with each other.
Pharmaceutical SEO behaves unlike consumer search. The terms that matter return a few dozen searches a month, in several languages, from a small number of people with real budget. Optimising for volume misses them entirely.
Technical SEO, international and multilingual targeting, migration continuity and redirect mapping, content architecture, AI search visibility, and the measurement setup underneath all of it.
Buying links, optimising for medical queries we are not qualified to answer, and promising positions. Nothing that would put a regulated company at risk for a short-term ranking is worth doing.
The clearest test of a pharmaceutical SEO agency is a domain change that does not reset the search history. These figures describe the crawlable surface we have had to preserve: documents, articles, scientific papers and country variants.
A distributor competes for hundreds of ingredient names. A laboratory competes for a dozen corporate terms. Pharmaceutical SEO tactics for the two have almost nothing in common.
What regulated companies ask about search visibility.
Usually yes, for the opposite reason to consumer sectors. The value is not traffic, it is who the traffic is. A handful of visits a month from procurement leads evaluating suppliers can justify the whole programme, and the competition for those terms is often close to zero.
Often, at least partly, and the sooner the better. It usually comes down to per-path redirects that were never mapped, a Search Console change of address that was not done, and old inbound links pointing at URLs that now return errors. We have run migrations where that mapping was done properly and the new domain kept its visibility.
This is the most common problem in international pharma groups. It is normally solved with correct language and region targeting, a clear canonical strategy and a decision about which market owns which term — not by writing more content, which usually makes it worse.
Only if it can be crawled. A large share of pharma catalogues are behind filters, scripts or gated downloads that search engines never reach. Fixing the structure normally produces more visibility than any content campaign, because the pages already exist.
It rewards being clearly citable. Direct answers, structured content and unambiguous factual statements get quoted; long undifferentiated pages do not. In a specialist vertical where few competitors have done this work, it is currently one of the cheapest advantages available.
No, and any agency that does is either guessing or simply bidding on your own brand name in paid search. We commit to the work itself and to measurement that separates branded from non-branded traffic, so you can see clearly whether real visibility and organic demand are growing over time, independent of any single ranking snapshot.
A migration that lost its rankings, a catalogue that never gets indexed, or country sites competing with each other. Tell us the context and we will tell you how we would approach the pharmaceutical SEO work.